CN107837250A - Applications of the Orientin in increased platelets counts medicine is prepared - Google Patents
Applications of the Orientin in increased platelets counts medicine is prepared Download PDFInfo
- Publication number
- CN107837250A CN107837250A CN201610825468.3A CN201610825468A CN107837250A CN 107837250 A CN107837250 A CN 107837250A CN 201610825468 A CN201610825468 A CN 201610825468A CN 107837250 A CN107837250 A CN 107837250A
- Authority
- CN
- China
- Prior art keywords
- orientin
- medicine
- prepared
- increased platelets
- applications
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses applications of the Orientin in increased platelets counts medicine is prepared, belong to technical field of new application of medicine, there is good development prospect.Belong to first public for applications of the Orientin of the present invention in increased platelets counts medicine is prepared, and its increased platelets counts activity is strong, has significant progressive.
Description
Technical field
The present invention relates to compound Orientin new application, more particularly to Orientin to prepare increased platelets counts medicine
In application.
Background technology
Compound Orientin of the present invention is one and delivers within 2013 (Ebenezer de Mello Cruz, et
al.,Leishmanicidal activity of Cecropia pachystachya flavonoids:Arginase
inhibition and altered mitochondrial DNA arrangement.Phytochemistry,89(2013)
71-77.) noval chemical compound, the compound possess brand-new framework types, and current purposes only suppresses hepatitis B
(Ebenezer de Mello Cruz, et al., Leishmanicidal activity of Cecropia
pachystachya flavonoids:Arginase inhibition and altered mitochondrial DNA
Arrangement.Phytochemistry, 89 (2013) 71-77.), Orientin of the present invention is small in preparation rise blood
Purposes in plate medicine belongs to first public.
The content of the invention
It is an object of the invention to do not find that it has the report of increased platelets counts activity in being studied according to existing Orientin
The present situation in road, there is provided applications of the Orientin in increased platelets counts medicine is prepared.
Shown in the compound Orientin structures such as formula (I)：
Applications of the Orientin in increased platelets counts medicine, Orientin can increase rat peripheral blood platelet count
Amount.
A kind of increased platelets counts medicine, it is that active component addition auxiliary material is prepared by Orientin, preparation method is to take 5
G of compound Orientin adds 195 grams of dextrin, mixes, and Conventional compression is made 1000.
A kind of increased platelets counts medicine, it is that active component addition auxiliary material is prepared by Orientin, preparation method is to take 5
G of compound Orientin adds 195 grams of starch, mixes, encapsulated to be made 1000.
Purposes of the Orientin of the present invention in treatment thrombocytopenia medicine is prepared belongs to first public, due to
Framework types belong to brand-new framework types, and it treats thrombocytopenia activity by force, possesses prominent substantive distinguishing features, together
When for thrombocytopenia preventing and treating obviously have it is significant progressive.
Embodiment
Compound Orientin involved in the present invention preparation method referring to document (Ebenezer de Mello Cruz,
et al.,Leishmanicidal activity of Cecropia pachystachya flavonoids:Arginase
inhibition and altered mitochondrial DNA arrangement.Phytochemistry,89(2013)
71–77.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by specific reality
Any restrictions of example are applied, but are defined in the claims.
Embodiment 1：The preparation of compound Orientin tablets involved in the present invention：
Take 5 g of compound Orientin to add 195 grams of dextrin, mix, Conventional compression is made 1000.
Embodiment 2：The preparation of compound Orientin capsules involved in the present invention：
Take 5 g of compound Orientin to add 195 grams of starch, mix, it is encapsulated to be made 1000.
Its pharmaceutical activity is further illustrated below by pharmacodynamic experiment.
Experimental example 1：Orientin hemoposieis：
First, the influence to mouse peripheral blood platelet counts is administered orally in Orientin
Method：Balb/c mouse 40,18-22g females, Nanjing Medical University's Experimental Animal Center, are divided into three by body weight
Group, respectively normal control, Orientin1mg/kg, Orientin 2mg/kg, it is divided within 1st and is administered orally twice, totally 9 times four
It half.Cutting within 1 day, 3 days, 7 days, 14 days tail before administration, after administration takes blood 20ul, F-820 platelet count instrument to detect blood picture.
The influence (n=10) to mouse peripheral blood platelet counts is administered orally in the Orientin of table 1
Compared with physiological saline group：*p<0.5**p<0.01
As a result：Hematoblastic major function is participation hemostasis.Platelet counts and dysfunction can cause bleeding to be inclined
To.Table 1 shows that the influence to rat peripheral blood platelet counts is administered orally in Orientin.As can be seen that same physiological saline group
Platelet count is compared, and administration group platelet counts have rise in 3-7 days upon administration, there is within 10-14 days a more obvious rise
Process.These results indicate that the Orientin of doses, which is administered orally, can increase rat peripheral blood platelet counts, this is
Orientin plays one of the effect of its hemoposieis.
2nd, therapeutic actions of the Orientin to post hemorrhagic mice
Influence ICR mouse 40 to post hemorrhagic mice, ♀ ♂ half and half, Nanjing Medical University's Experimental Animal Center, are divided into 4
Group (n=10).In addition to physiological saline group, other groups of every mouse take blood to survey all again after orbital vein bloodletting 0.5ml, 24h
Each group index, then continuous gavage be administered 1 week, after last dose 1h, the full plaque assays of blood F-800 are taken from orbital venous plexus
Instrument surveys These parameters.
Therapeutic actions of the Orientin of table 2 to the decrease of platelet caused by losing blood
Compared with model group：*p<0.05**p<0.01
As a result showing, after taking Orientin and treating 7 days, 2 administration groups compare bloodletting mouse respectively at model group, its
Blood platelet value is significantly higher than model group, and has exceeded the level of normal saline group mouse.
3rd, the therapeutic action that Orientin reduces to coagulation function caused by radiation
To study the therapeutic action to acute radiation sickness, the Orientin for observing various dose irradiates mouse to 6.5Gy
The influence of Radiation in jury.
Therapeutic actions (10th day) of the Orientin of table 4 to decrease of platelet caused by radiation
Compared with modeling group：*p<0.05**p<0.01
As a result show, give after by the daily Orientin 0.5 and 2.0mg/kg treatments of photograph mouse, hematoblastic Restoration model
Accelerate, be preferred with 2.0mg dosage group effects.
Conclusion：Orientin can notable increased platelets counts, can be used for preparing the medicines of increased platelets counts.
Claims (4)
- Applications of the 1.Orientin in increased platelets counts medicine, shown in the compound Orientin structures such as formula (I)：
- 2. applications of the Orientin as claimed in claim 1 in increased platelets counts medicine, it is characterised in that Orientin can increase Increase mouse peripheral blood platelet counts.
- 3. a kind of increased platelets counts medicine, it is characterised in that the Orientin as described in claim 1 is that active component adds auxiliary material It is prepared, preparation method mixes, Conventional compression is made 1000 to take 5 g of compound Orientin to add 195 grams of dextrin.
- 4. a kind of increased platelets counts medicine, it is characterised in that the Orientin as described in claim 1 is that active component adds auxiliary material It is prepared, for preparation method to take 5 g of compound Orientin to add 195 grams of starch, mixing is encapsulated to be made 1000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610825468.3A CN107837250A (en) | 2016-09-18 | 2016-09-18 | Applications of the Orientin in increased platelets counts medicine is prepared |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610825468.3A CN107837250A (en) | 2016-09-18 | 2016-09-18 | Applications of the Orientin in increased platelets counts medicine is prepared |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107837250A true CN107837250A (en) | 2018-03-27 |
Family
ID=61656483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610825468.3A Pending CN107837250A (en) | 2016-09-18 | 2016-09-18 | Applications of the Orientin in increased platelets counts medicine is prepared |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107837250A (en) |
-
2016
- 2016-09-18 CN CN201610825468.3A patent/CN107837250A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107837250A (en) | Applications of the Orientin in increased platelets counts medicine is prepared | |
| CN103271913A (en) | Application of Myriberine A in preparing thrombocyte-increasing medicines | |
| CN101912437B (en) | Chinese medicinal composition for improving bone marrow depression caused by radiotherapy and chemotherapy and preparation method thereof | |
| CN107854463A (en) | Applications of the Apigenin in increased platelets counts medicine is prepared | |
| CN107854475A (en) | Isovitexin is preparing the application in raising red blood cell medicine | |
| CN107854458A (en) | Apigenin is preparing the application in raising red blood cell medicine | |
| CN103751178B (en) | The application of Trigoxyphin K in increased platelets counts medicine | |
| CN103462956B (en) | Application of Nardoaristolones A in preparation of medicaments for increasing erythrocytes | |
| CN103720686B (en) | Trigoxyphin K is raising the application in erythrocyte medicine | |
| CN105343108A (en) | Application of Astataricusones B in preparing blood platelet increasing medicine | |
| CN103372018B (en) | The application of Chukrasone A in the medicine of preparation increased platelets counts | |
| CN105287542A (en) | Application of Densanins A in preparation of blood platelet increasing medicine | |
| CN105878238A (en) | Pharmaceutical composition for increasing blood platelets, and preparation method and application thereof | |
| CN106265647A (en) | Ternatusine A application in preparation increased platelets counts medicine | |
| CN107854455A (en) | Dysidavarone A are preparing the application in raising red blood cell medicine | |
| CN105456272A (en) | Application of Biscarpamontamine A in preparing medicine for increasing red blood cells | |
| CN105456244A (en) | Application of Flabelliferin A in preparation of platelet improving drugs | |
| CN103417549B (en) | Application of compound Kadcoccitones A in preparation of erythrocyte increasing drugs | |
| CN105380952A (en) | Application of Astataricusones C in preparation of drugs for raising erythrocyte level | |
| CN105287523A (en) | Use of Alistonitrine A in preparation of drug for increasing platelet | |
| CN102872047B (en) | Application of Gypensapogenin A in medicament for increasing level of blood platelets | |
| CN106491615A (en) | Applications of the Friedolanostanes in increased platelets counts medicine is prepared | |
| CN106309429A (en) | Application of Linderolide-H in preparation of medicaments for increasing erythrocytes | |
| CN107837260A (en) | Apigenin is preparing the application in treating acute renal failure medicine | |
| CN105343066A (en) | Application of Herqueidiketal in preparing erythrocyte increasing medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180327 |